Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia

Launched by RIGSHOSPITALET, DENMARK · Nov 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the long-term health effects that childhood survivors of Acute Lymphoblastic Leukemia (ALL) face after their treatment. Researchers want to find out how many of these survivors live without experiencing severe health problems, called Severe Toxicities, in the first five years after being diagnosed. They will look at data from children diagnosed with ALL in the last five years to understand the average number and types of these serious health issues.

To be eligible for this study, participants must have been diagnosed with ALL when they were under 18 years old and must have completed their treatment at least five years ago. There are no exclusions based on other health conditions. If you or your child join this study, you can expect to share your health information, which will help researchers learn more about the challenges faced by ALL survivors and improve future care for children with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with ALL ≥5 years ago
• • \<18 years of age at time of ALL diagnosis
• Exclusion Criteria:
• • None

Trial Officials